Skip to content

Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder System

Prospective Post Market Clinical Follow-up Study of the Zimmer Trabecular Metal Reverse Should System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01480440
Enrollment
200
Registered
2011-11-28
Start date
2011-01-01
Completion date
2026-12-01
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Avascular Necrosis, Gross Rotator Cuff Deficiency, Irreducible 3-and 4-part Proximal Humeral Fractures, Osteoarthritis, Post-traumatic Arthritis, Revision Total Shoulder Arthroplasty, Rheumatoid Arthritis, Ununited Humeral Head Fracture

Keywords

Reverse Total Shoulder Arthroplasty (TSA), Reverse TSA, Osteoarthritis, Rheumatoid Arthritis, Post-traumatic arthritis, Ununited humeral head fracture, Irreducible 3-and 4-part proximal humeral fractures, Avascular necrosis, Gross rotator cuff deficiency, Failed total shoulder arthroplasty, Revision total shoulder arthroplasty

Brief summary

The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty.

Detailed description

The objectives of this study are to obtain survival and outcome data on the Trabecular Metal Reverse Shoulder System when used in primary or revision reverse total shoulder arthroplasty. This will be done by analysis of standard scoring systems, radiographs and adverse event records. Data will be collected and analyzed to monitor pain, function, and survivorship and to confirm the performance of the Trabecular Metal Reverse Shoulder System. Performance will be evaluated by monitoring the frequency and incidence of adverse events as well as by assessment of the overall pain and functional performances, survivorship, health status and radiographic parameters of all enrolled study subjects who receive the Trabecular metal Reverse Shoulder System. Pain and functional performance will be measured using the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE), survivorship will be based on removal or intended removal of the device, health status will be determined by evaluation of the Short Form Survey12 (SF-12) as well as Adverse Events (AEs) and radiographic parameters analysis of x-rays.

Interventions

DEVICETrabecular Metal Reverse Shoulder System

Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty

Sponsors

Zimmer Biomet
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient is \> 18 years of age; * Patient is skeletally mature; * Patient qualifies for primary or revision unilateral or bilateral reverse total shoulder arthroplasty based on physical exam and medical history including the following: osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, ununited humeral head fracture, irreducible 3-and 4-part proximal humeral fractures, avascular necrosis, gross rotator cuff deficiency or failed total shoulder arthroplasty (both glenoid and humeral components require revision); * Patient is willing and able to provide written informed consent; * Patient is willing and able to cooperate in the required post-operative therapy; * Patient is willing and able to complete scheduled follow-up evaluations/questionnaires as described in the Informed Consent; * Patient has participated in the Informed Consent process and has signed the Institutional Review Board (IRB)/Ethical Review Board (ERB) approved informed consent.

Exclusion criteria

* The patient is a prisoner; * The patient is mentally incompetent or unable to understand what participation in the study entails; * The patient is a known alcohol or drug abuser; * The patient is anticipated to be non-compliant; * The patient has one of the following compromising the affected limb: a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable; * The patient has a local/systemic infection; * The patient is known to be pregnant; * The patient has marked bone loss; * The patient has a known sensitivity or allergic reaction to one or more of the implanted materials; * The patient is unwilling or unable to give consent or to comply with the follow-up program.

Design outcomes

Primary

MeasureTime frameDescription
Survivorship10 YearsBased on removal or intended removal of the device and determined using the Kaplan-Meier method.

Secondary

MeasureTime frameDescription
Pain and Functional Performance10 YearsMeasurements will be based on the American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment and the Single Assessment Numeric Evaluation (SANE)

Countries

United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 29, 2026